Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2676
Registo completo
Campo DCValorIdioma
dc.contributor.authorMarques da Silva, P-
dc.identifier.citationClin Drug Investig. 2010;30(9):625-41pt_PT
dc.description.abstractEarly initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outcomes in patients with hypertension. Once-daily combination therapy provides more rapid control of BP, which is important for preventing cardiovascular events, with similar or improved tolerability compared with the component monotherapies, and improved adherence because of regimen simplification. Combination therapy with a calcium channel antagonist (calcium channel blocker [CCB]) and an inhibitor of the renin-angiotensin-aldosterone system (RAAS) is a rational approach to achieve BP goals and provide protection against renal and cardiovascular morbidity and mortality. A number of CCB/RAAS inhibitor combinations, including CCB/angiotensin-converting enzyme (ACE) inhibitor and CCB/ angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) combinations are available as fixed-dose formulations. There is substantial evidence for the BP-lowering efficacy of CCB/RAAS inhibitor combinations in diverse patient populations, and their use in combination is associated with favourable tolerability and fewer adverse metabolic effects than some other combination therapies. Recent evidence from large outcome trials supports the use of CCB/RAAS inhibitor combinations for reducing the risk of cardiovascular and renal events, particularly in high-risk patients, together with evidence that the benefits of CCB/RAAS inhibitor combinations may extend beyond their efficacy in lowering BP in terms of protecting against fatal and nonfatal stroke, myocardial infarction and cardiovascular-related deaths. The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years. Fixed-dose amlodipine/valsartan combinations are available in many countries and have shown greater BP reductions and better BP control than the respective monotherapies in diverse patient populations, together with a favourable tolerability profile. Once-daily amlodipine/valsartan is a rational and convenient treatment option for the effective management of patients with hypertension, improving adherence to antihypertensive medication and protecting against cardiovascular and renal morbidity and mortality.pt_PT
dc.publisherSpringer Verlagpt_PT
dc.subjectAmlodipine, Valsartan Drug Combinationpt_PT
dc.subjectAngiotensin II Type 1 Receptor Blockerspt_PT
dc.subjectAntihypertensive Agentspt_PT
dc.subjectBlood Pressurept_PT
dc.subjectCalcium Channel Blockerspt_PT
dc.subjectDrug Combinationspt_PT
dc.subjectTreatment Outcomept_PT
dc.subjectHSM MEDpt_PT
dc.titleEfficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension: Focus on Amlodipine/valsartanpt_PT
degois.publication.titleClinical Drug Investigationpt_PT
Aparece nas colecções:MED - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Clin Drug Invest 2010 625.pdf458,76 kBAdobe PDFVer/Abrir

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.